AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
- Details
- Category: AstraZeneca
AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company's key therapeutic areas.
Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company's immuno-oncology (I-O) portfolio.
Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial
- Details
- Category: GlaxoSmithKline
GSK has announced that the first batch of its candidate Ebola vaccine is being shipped to west Africa and is expected to arrive in Liberia later today Friday 23 January. The shipment, containing an initial 300 vials of the candidate vaccine, is the first to arrive in one of the main Ebola affected countries and will be used to start the first large-scale efficacy trial of experimental Ebola vaccines in the coming weeks.
Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos's proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA - a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children.
Novartis Pharmaceuticals announces a joint investment company with Qualcomm
- Details
- Category: Novartis
Novartis Pharmaceuticals has announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies who offer technologies, products or services that "go beyond the pill" to benefit physicians and patients.
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ: FMI) announced today that they will enter into a broad strategic collaboration to further advance FMI's market-leading position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients.
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses.
More Pharma News ...
- Acquisition provides Pfizer with a preclinical CMV vaccine candidate
- Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
- Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) sign worldwide research collaboration
- New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine
- Abbott completes acquisition of Veropharm
- Pfizer expands rare disease research with establishment of gene therapy platform
- Jury verdict favours AstraZeneca in Nexium antitrust litigation